Co-administration of CD20-targeting bispecific antibodies with CD19-CAR in lymphoma
Brinkmann BJ, Floerchinger A, Schniederjohann C, et al. CD20-Bispecific Antibodies Improve Response to CD19-CAR T-Cells in Lymphoma In-Vitro and CLL In-Vivo Models. Blood. 2024; (doi: 10.1182/blood.2023022682).
The efficacy of anti-CD19 chimeric antigen receptor T-cells (CD19-CAR) against relapsed/refractory B-cell malignancies can be amplified by co-administering them alongside CD20-targeting bispecific antibodies (CD20-BsAb), scientists report. As demonstrated in an immunocompetent mouse model of chronic lymphocytic leukemia, the approach increased eradication of malignant cells. At the same time, activation and proliferation improved for both endogenous T-cells and infused CD19-CAR T-cells. The result was enhanced disease control and longer survival, with 80% of mice cured within 8 weeks of starting treatment, as defined by no detectable malignant cell population.